Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure

We provide preliminary evidence that treatment with the novel cell population, ALDHbr cells, is safe and may provide perfusion and functional benefits in patients with chronic myocardial ischemia.